	US 12,478,581 B2
	Powder formulation for intranasal administration, and manufacturing method thereof
Shunji Haruta, Kagoshima (JP); and Yo Sonoda, Kagoshima (JP)
Assigned to Shin Nippon Biomedical Laboratories, Ltd., Kagoshima (JP)
Appl. No. 17/595,381
Filed by SHIN NIPPON BIOMEDICAL LABORATORIES, LTD., Kagoshima (JP)
PCT Filed May 1, 2020, PCT No. PCT/JP2020/018456 § 371(c)(1), (2) Date Nov. 15, 2021, PCT Pub. No. WO2020/230676, PCT Pub. Date Nov. 19, 2020.
Claims priority of application No. 2019-093150 (JP), filed on May 16, 2019.
Prior Publication US 2022/0183971 A1, Jun. 16, 2022
Int. Cl. A61K 9/19 (2006.01); A61K 9/00 (2006.01); A61K 9/50 (2006.01); A61K 45/06 (2006.01)

CPC A61K 9/0075 (2013.01) [A61K 9/19 (2013.01); A61K 9/5036 (2013.01); A61K 9/5084 (2013.01); A61K 45/06 (2013.01)]

13 Claims

1. A medicament comprising a powder formulation for intranasal administration,

wherein the powder formulation comprises composite particles in which an active ingredient and a crystalline cellulose are cohered to each other,

wherein the active ingredient is levodopa,

wherein the crystalline cellulose has an average particle size of about 20 μm and a bulk density of about 0.23 g/cm³, and

wherein the composite particles remain cohered at a dispersive pressure of 2 bar.